Castle Biosciences Q1 revenue $83.7M; core tests +36%; raises FY guidance to $345-355M

CASTLE BIOSCIENCES INC

2026-Q1 EPS reported -$0.49 revenue$83,679,000

Revenue $83.7M vs $88.0M Q1 2025; core test reports +36% YoY (DecisionDx-Melanoma +16%, TissueCypher +58%).
Net loss improved to $14.5M ($0.49/share) from $25.8M ($0.90); adjusted EBITDA -$5.1M vs +$13.0M.
Raises FY2026 revenue guidance to $345-355M from $340-350M; cash & investments $261.7M.
Gross margin 73% (adj. 76%) vs 49% (adj. 81%) prior year, which included $20.1M amortization acceleration.
Operating cash use $22.1M includes $28.8M in one-time bonus/benefit payments not expected to recur in 2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CASTLE BIOSCIENCES INC reported first quarter ended March 31, 2026 results: revenue $83.7 million, net income $14.5 million, EPS $0.49. Guidance raised.

Period: first quarter ended March 31, 2026
Revenue: $83.7 million
Net income: $14.5 million
EPS: $0.49
Guidance: raised
Result: reported results

Exact text from the filing

Castle Biosciences Reports First Quarter 2026 Results Delivered Q1 2026 revenue of $83.7 million

View on SEC.gov

Browse all earnings releases →

CASTLE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0001628280-26-031255

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.